Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-01-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: carcinomacelland neckhead andsquamous
  Phrases that lowered it: pulmonaryupperbleedinglungmale
• Sponsor's past termination rate: 57.1% (raises risk) · Sponsor's track record
• Design: factorial (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports marked serious: 95.3% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 31186 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 4877 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History NCT01758731 · started 2012 · scored riskier than 41% of active trials completed
• Pembrolizumab and Olaparib in Cervical Cancer Patients NCT04483544 · started 2020 · scored riskier than 81% of active trials terminated
• Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN NCT04939480 · started 2021 · scored riskier than 95% of active trials completed
• Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin NCT03100006 · started 2017 · scored riskier than 62% of active trials terminated
• Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab NCT03612791 · started 2018 · scored riskier than 83% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.